Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10096-003-1036-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A two-sample mendelian randomization study of non-tuberculous mycobacteria infection and lung cancer.
J Thorac Dis
December 2024
Department of Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong, China.
Background: Non-tuberculous mycobacterial lung disease may coexist or precede lung cancer, yet a causal link remains unproven. This study aimed to elucidate the causal association between non-tuberculous mycobacteria (NTM) and lung cancer.
Methods: Summary data from genome-wide association studies (GWAS) for NTM, atypical mycobacterial lung infections, and various types of lung cancer were utilized.
Restriction of mitochondrial oxidation of glutamine or fatty acids enhances intracellular growth of in macrophages.
Virulence
December 2025
Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon, South Korea.
(Mab), a nontuberculous mycobacterium, is increasing in prevalence worldwide and causes treatment-refractory pulmonary diseases. However, how Mab rewires macrophage energy metabolism to facilitate its survival is poorly understood. We compared the metabolic profiles of murine bone marrow-derived macrophages (BMDMs) infected with smooth (S)- and rough (R)-type Mab using extracellular flux technology.
View Article and Find Full Text PDFNew Frontiers in Fighting Mycobacterial Infections: Venom-Derived Peptides.
Probiotics Antimicrob Proteins
January 2025
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
Notwithstanding the indefatigable endeavors to develop effective anti-mycobacterial therapies, mycobacterial infections still present a tough problem for medicine today. The problem is further complicated by the disquieting surge of drug-resistant mycobacterial pathogens, which considerably narrows the existing therapeutic options. Thus, there is a genuine need to discover novel anti-mycobacterial drugs.
View Article and Find Full Text PDFNew Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on ).
Antimicrob Agents Chemother
January 2025
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky, USA.
Omadacycline is a novel antimicrobial belonging to the tetracycline class. It has the ability to evade both efflux and ribosomal methylation types of resistance and therefore has an expanded spectrum compared to other tetracycline agents. Omadacycline is active against a number of multidrug-resistant bacteria, including macrolide and doxycycline-resistant methicillin-resistant (MRSA), vancomycin-resistant Enterococcus, and several enteric gram-negative bacilli.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!